Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results

Rhinoviruses (RVs) cause the common cold and are associated with exacerbations of chronic inflammatory respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). We have assessed the antiviral drugs Anaferon for Children (AC) and Ergoferon (containing AC as one of the...

Full description

Saved in:
Bibliographic Details
Published in:Antiviral research 2017-06, Vol.142, p.185
Main Authors: Petrova, Nataliia V, Emelyanova, Alexandra G, Gorbunov, Evgeniy A, Edwards, Michael R, Walton, Ross P, Bartlett, Nathan W, Aniscenko, Julia, Gogsadze, Leila, Bakhsoliani, Eteri, Khaitov, Musa R, Johnston, Sebastian L, Tarasov, Sergey A, Epstein, Oleg I
Format: Article
Language:English
Subjects:
2',5'-Oligoadenylate Synthetase - analysis
Animals
Antibodies - pharmacology
Antiviral Agents - immunology
Antiviral Agents - pharmacology
Asthma - immunology
Asthma - virology
Cell Line
Chemokines - metabolism
Child
Cytokines - drug effects
Cytokines - metabolism
Disease Models, Animal
Gene Expression - drug effects
HeLa Cells
Humans
Inflammation
Interferons - drug effects
Mice
Mice, Inbred BALB C
Picornaviridae Infections - drug therapy
Respiratory System - immunology
Respiratory System - virology
Rhinovirus - drug effects
Rhinovirus - pathogenicity
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Rhinoviruses (RVs) cause the common cold and are associated with exacerbations of chronic inflammatory respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). We have assessed the antiviral drugs Anaferon for Children (AC) and Ergoferon (containing AC as one of the active pharmaceutical ingredients) in in vitro and in vivo experimental models, in order to evaluate their anti-rhinoviral and immunomodulatory potential. HeLa cells were pretreated with AC, and levels of the interferon-stimulated gene (ISG), 2'-5'-oligoadenylate synthetase 1 (OAS1-A) and viral replication were analyzed. In a mouse model of RV-induced exacerbation of allergic airway inflammation we administered Ergoferon and analyzed its effect on type I (IFN-β), type II (IFN-γ) and type III (IFN-λ) IFNs induction, cell counts in bronchoalveolar lavage (BAL), cytokine (interleukin (IL)-4; IL-6) and chemokine (CXCL10/IP-10; CXCL1/KC) levels. It was shown that AC increased OAS1-А production and significantly decreased viral replication in vitro. Increased IFNs expression together with reduced neutrophils/lymphocytes recruitment and correlated IL-4/IL-6 declination was demonstrated for Ergoferon in vivo. However, there was no effect on examined chemokines. We conclude that AC and Ergoferon possess effects against RV infection and may have potential as novel therapies against RV-induced exacerbations of asthma.
ISSN:1872-9096
DOI:10.1016/j.antiviral.2017.03.017